Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

e III endpoint is substantially smaller than the 33% increase seen in Phase II.
  • No toxicity issues have been identified.
  • No safety issues have been identified.
  • Clear unmet medical need.
  • FDA granted Multikine Orphan Drug status in the USA.

  • Our clinical success would be huge since Multikine would be on course to become the recommended first-line treatment for head and neck cancer. From there, we could hopefully prove that Multikine is likely to work against other solid tumors as well.

    Our ultimate goal in development is to provide patients and physicians with a new and better way of fighting cancer. We believe that the key to doing so lies in our immune system. Dendreon's prostate cancer vaccine recently established that this is possible. Their success is even more impressive because they focused on late-stage cancer patients. We believe that Multikine should have an even greater chance of success because we focus on patients not yet treated for their cancer. Their immune system is still intact, except in the area of the tumor, and their lymphatics have not yet been cut, meaning that they can still deliver immune cells from the local lymph nodes to the tumor.

    From here on there is only one thing to do. We will launch the Phase III study as quickly as possible. Success would be phenomenal, and we anticipate that it should enable rapid approval around the world.

    We thank you for your continued support.

    Sincerely,

    Geert Kersten

    Chief Executive Officer

    When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected.
    '/>"/>

    SOURCE CEL-SCI Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. CEL-SCI to Present at the Noble Financial Conference
    2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
    3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
    4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    5. CEL-SCI Takes Delivery of New Manufacturing Facility
    6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
    7. CEL-SCI Corporation Releases Letter to Shareholders
    8. CEL-SCI Corporation Announces 2008 Financial Results
    9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
    10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
    11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... an electronic which is not only based on ... spin and the spin-related magnetism. Spin-charge converters enable ... vice versa. Recently, the research group of Professor ... Johannes Gutenberg University Mainz in collaboration with researchers ... the first time realised a new, efficient spin-charge ...
    (Date:8/28/2014)... (PRWEB) August 28, 2014 The ability ... a culture that will allow individuals to perform at ... increasingly important for employers looking to compete in this ... are embracing this trend, as the sector increasingly focuses ... a company, which will have real results on the ...
    (Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
    (Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
    Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
    ... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 ... , , , , , ... , Cell type , ...
    ... Kits , , ... Eppendorf Perfectprep Plasmid DNA Isolation Kits are designed to generate , ... automated fluorescent , sequencing, transfection, PCR, and other extremely ... In order to compare yields between our kits and the leading competitor, ...
    ... , Other important parameters for optimizing electroporation., , , , , , ... , Pulse length , ... Adjustment , of the electroporation buffer , ... Influence , of temperature , ...
    Cached Biology Technology:Actinomyces viscosus 2Eppendorf Perfectprep Plasmid DNA Isolation , Kits 2Eppendorf Perfectprep Plasmid DNA Isolation , Kits 3Optimizing electroporation parameters 2
    (Date:8/28/2014)... the developmental on-off switch for Streptomyces , a ... of the world,s naturally derived antibiotic medicines. , ... is possible to manipulate this switch to make nature,s ... August 28 in Cell , found that a ... a larger protein called BldD ultimately controls whether a ...
    (Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) ... the American College of Sports Medicine,s Conference on ... in Miami, Florida. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the American ...
    (Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability in ... that occurs when the regions of the brain ... The use of non-invasive functional neuroimaging tools has ... dyslexia. However, most prior work has focused on ... a gap in our understanding of how multiple ...
    Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Dyslexic readers have disrupted network connections in the brain 2
    ... National data indicate that milk consumption has declined ... nutritional quality has more than doubled. Although this suggests ... in children,s diets, a new study suggests that in ... related to changes in their consumption of sodas and ...
    ... at the California Institute of Technology (Caltech) pioneered ... the immune system and neurodevelopmental disorders such as ... postmortem brains and of individuals with autism, as ... between alterations in the immune system and autism ...
    ... is a vital nutrient for pig growth, but pigs ... the University of Illinois has determined how adding various ... how pigs digest the phosphorus in four different feed ... bottom lines as well as for the environment. ...
    Cached Biology News:Sugar-sweetened drinks are not replacing milk in kid's diets 2Sugar-sweetened drinks are not replacing milk in kid's diets 3Caltech researchers find evidence of link between immune irregularities and autism 2Caltech researchers find evidence of link between immune irregularities and autism 3Helping pigs to digest phosphorus 2Helping pigs to digest phosphorus 3
    Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
    Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
    Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
    ... gun system, 220-240 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
    Biology Products: